The nature of and behavioral treatment of sleep problems in youth with bipolar disorder.

2007 ◽  
Vol 3 (1) ◽  
pp. 88-95 ◽  
Author(s):  
Lisa A. Schwartz ◽  
Norah C. Feeny
Keyword(s):  
Bipolar Disorder ◽  
Behavioral Treatment ◽  
Sleep Problems

scholarly journals Repetitive transcranial magnetic stimulation in the treatment of bipolar disorder

2020 ◽  
Vol 10 ◽  
pp. 204512532097379
Author(s):  
Danielle Hett ◽  
Steven Marwaha
Keyword(s):  
Bipolar Disorder ◽  
Transcranial Magnetic Stimulation ◽  
Side Effects ◽  
Magnetic Stimulation ◽  
Sleep Problems ◽  
Bipolar Depression ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Controlled Trial ◽  
Total N ◽  
Depressive Episodes

Bipolar disorder (BD) is a debilitating mood disorder marked by manic, hypomanic and/or mixed or depressive episodes. It affects approximately 1–2% of the population and is linked to high rates of suicide, functional impairment and poorer quality of life. Presently, treatment options for BD are limited. There is a strong evidence base for pharmacological (e.g., lithium) and psychological (e.g., psychoeducation) treatments; however, both of these pose challenges for treatment outcomes (e.g., non-response, side-effects, limited access). Repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, is a recommended treatment for unipolar depression, but it is unclear whether rTMS is an effective, safe and well tolerated treatment in people with BD. This article reviews the extant literature on the use of rTMS to treat BD across different mood states. We found 34 studies in total ( N = 611 patients), with most assessing bipolar depression ( n = 26), versus bipolar mania ( n = 5), mixed state bipolar ( n = 2) or those not in a current affective episode ( n = 1). Across all studies, there appears to be a detectable signal of efficacy for rTMS treatment, as most studies report that rTMS treatment reduced bipolar symptoms. Importantly, within the randomised controlled trial (RCT) study designs, most reported that rTMS was not superior to sham in the treatment of bipolar depression. However, these RCTs are based on small samples ( NBD ⩽ 52). Reported side effects of rTMS in BD include headache, dizziness and sleep problems. Ten studies ( N = 14 patients) reported cases of affective switching; however, no clear pattern of potential risk factors for affective switching emerged. Future adequately powered, sham-controlled trials are needed to establish the ideal rTMS treatment parameters to help better determine the efficacy of rTMS for the treatment of BD.

Inactograms and objective sleep measures as means to capture subjective sleep problems in patients with a bipolar disorder

2020 ◽  
Vol 22 (7) ◽  
pp. 722-730
Author(s):  
Paola Lavin‐Gonzalez ◽  
Clément Bourguignon ◽  
Olivia Crescenzi ◽  
Serge Beaulieu ◽  
Kai‐Florian Storch ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Sleep Problems ◽  
Subjective Sleep

RAINBOW

2017 ◽  
Author(s):  
Amy E. West ◽  
Sally M. Weinstein ◽  
Mani N. Pavuluri
Keyword(s):  
Bipolar Disorder ◽  
Mental Health Professionals ◽  
Behavioral Treatment ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Treatment Manual ◽  
Good Friend ◽  
Pediatric Bipolar Disorder ◽  
Cognitive Behavioral Treatment ◽  
Behavioral Strategies

RAINBOW: A Child- and Family-Focused Cognitive-Behavioral Treatment for Pediatric Bipolar Disorder is a comprehensive, evidence-based treatment manual designed specifically for children ages 7–13 with bipolar spectrum disorders and their families. Developed by experts in pediatric mood disorders and tested in a randomized clinical trial (RCT), RAINBOW integrates psychoeducation and cognitive-behavioral therapy (CBT) with complementary techniques from mindfulness-based intervention, positive psychology, and interpersonal therapy to address the range of therapeutic needs of families affected by this disorder. Guided by the evidence on the neurobiological and psychosocial difficulties accompanying pediatric bipolar disorder, this treatment targets the child and family across seven core components: Routine, Affect Regulation, I Can Do It, No Negative Thoughts and Live in the Now, Be a Good Friend/Balanced Lifestyle for Parents, Oh How Do We Solve This Problem, and Ways to Get Support. Throughout the treatment, the child and family will learn how to identify mood states and triggers of mood dysregulation, and develop cognitive and behavioral strategies for improving mood stability. Children will build social skills, and caregivers will develop greater balance and self-care in their own lives. The family will learn ways to use routines, problem-solving, and social support to improve overall family functioning. Intended for qualified child-focused mental health professionals, this manual includes the conceptual background of the treatment and user-friendly step-by-step instruction in delivering RAINBOW with families, including handy session outlines and engaging worksheets for the child and caregiver(s).

Sleep-Related Functioning in Euthymic Patients With Bipolar Disorder, Patients With Insomnia, and Subjects Without Sleep Problems

2005 ◽  
Vol 162 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Allison G. Harvey ◽  
D. Anne Schmidt ◽  
Antonina Scarnà ◽  
Christina Neitzert Semler ◽  
Guy M. Goodwin
Keyword(s):  
Bipolar Disorder ◽  
Sleep Problems

Controversies in Behavioral Treatment of Sleep Problems in Young Children

2014 ◽  
Vol 9 (2) ◽  
pp. 251-259 ◽  
Author(s):  
Jocelyn H. Thomas ◽  
Melisa Moore ◽  
Jodi A. Mindell
Keyword(s):  
Young Children ◽  
Behavioral Treatment ◽  
Sleep Problems

scholarly journals From Animal Models to Behavioral Treatment of Bipolar Disorder

2017 ◽  
Vol 30 ◽  
Author(s):  
R. Nicolle Matthews-Carr
Keyword(s):  
Bipolar Disorder ◽  
Animal Models ◽  
Behavior Therapy ◽  
Behavioral Treatment ◽  
Medication Compliance ◽  
Face Validity ◽  
Third Wave ◽  
Treatment Models ◽  
Treatment Package ◽  
New Treatment

Bipolar disorder is difficult to capture in a single animal model, so far proving impossible. Models have evaluated the neurobiological, genetic, pharmacological and behavioral aspects, both in seclusion and in various combinations, but have yet to prove construct or face validity or led to highly effective treatment models. One area where animal models are having success is when animal models shape behavioral treatment. Third wave behavioral therapies and Applied Behavior Analysis (ABA) have shown decreased relapse and re-hospitalization at 1 year follow up, increased medication compliance and increased family support. Cognitive Behavior Therapy (CBT), Dialectal Behavior Therapy (DBT) and Family Focused Treatment (FFT) that include problem solving, family education and self-management have shown success across setting such as school, home and community, especially when used as part of the overall treatment package with medication. While a single model is unable to encompass all areas of need for a disorder as complex as bipolar disorder, continued research should allow for new treatment models to emerge

scholarly journals 664 Characteristics of respondents to a virtual trial of a digital behavioral treatment for insomnia during the COVID-19 pandemic

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A259-A260
Author(s):  
Frances Thorndike ◽  
Keith Saver ◽  
Stephen Braun ◽  
Karren Williams ◽  
Xiaorui Xiong
Keyword(s):  
Clinical Trial ◽  
Behavioral Treatment ◽  
Sleep Problems ◽  
Behavioral Therapy ◽  
Medication Use ◽  
Severity Index ◽  
Alternative Methods ◽  
Open Label ◽  
Fda Guidance ◽  
The Impact

Abstract Introduction Rates of sleep disturbance and sleep medication use have increased during the COVID-19 pandemic, at a time when face-to-face delivery of behavioral insomnia treatments is severely limited. To support research during the pandemic, the FDA released guidelines promoting the use of “alternative methods” to conduct trials in a virtual or decentralized manner. Currently, few data exist regarding the impact of virtual trial enrollment during a pandemic. This abstract presents data from a decentralized, open-label, single-arm real-world clinical trial of the Somryst prescription digital therapeutic for insomnia, which provides insight on who seeks care for insomnia using virtual research methods. Methods In alignment with FDA guidance, the DREAM trial began enrolling patients in March, 2020 with an expected final sample size of 350 adults (Clinical Trial # NCT04325464). This abstract presents data from participants seeking enrollment into the trial via an online screening. Demographic and sleep variables were collected to confirm eligibility. Results Of 1,063 respondents, the majority were female (62%) and the most common age brackets were ages 30–39 (22%); 40–49 (20%); and 50–59 (20%). Most respondents (63.8%) did not report being under the care of a healthcare provider for their insomnia. Respondents reported sleep problems for an average of 12.9 years; sleep problems 5 nights/week; and sleeping an average of 5.4 hours/night. Geographic diversity was high with respondents from 45 states and Washington DC. Of those passing initial screening (N=270), 5.5% reported having another diagnosed sleep disorder, 14.4% reported a comorbid psychological condition, 58.9% reported taking a medication for insomnia, and 30.7% reported taking a medication for depression. Using the Insomnia Severity Index, 16.7% had subthreshold/mild insomnia (score 8–14), 60.0% had moderate insomnia (score 15–21), and 23.7% had severe insomnia (score > 21). Conclusion Respondents to this decentralized trial reported moderate-severe, long-lasting insomnia with high rates of medication use for sleep and depression. Results demonstrate that virtual trials can quickly draw a highly geographically diverse research population, overcoming logistical challenges inherent in a pandemic and resulting in recruiting appropriate, but more geographically diverse, samples than those typically observed in randomized trials of cognitive behavioral therapy for insomnia (CBT-I). Support (if any):

Evaluation of a behavioral treatment package to reduce sleep problems in children with Angelman Syndrome

2013 ◽  
Vol 34 (1) ◽  
pp. 676-686 ◽  
Author(s):  
Keith D. Allen ◽  
Brett R. Kuhn ◽  
Kristi A. DeHaai ◽  
Dustin P. Wallace
Keyword(s):  
Angelman Syndrome ◽  
Behavioral Treatment ◽  
Sleep Problems ◽  
Treatment Package
Sign in / Sign up

Export Citation Format

Share Document